The PI3′ kinase pathway in interferon signaling

Journal of Interferon and Cytokine Research

Volumn 25, Issue 12, 2005, Pages 780-787

  Kaur, Surinder ^a   Uddin, Shahab ^b   Platanias, Leonidas C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; STAT PROTEIN; INSULIN RECEPTOR; PROTEIN KINASE B; SERINE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; CELL SURVIVAL; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; IMMUNOMODULATION; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; ENZYME ACTIVATION; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN SYNTHESIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; CELL SURVIVAL; ENZYME ACTIVATION; HUMANS; INTERFERONS; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, INSULIN; RNA, MESSENGER; SERINE; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 30344464664     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2005.25.780     Document Type: Review

References (86)

1. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu. Rev. Biochem. 1987;56:727-777.
2. Pestka, S. The interferon receptors. Semin. Oncol. 1997;24:S9-18-S9-40.
3. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu. Rev. Biochem. 1998;67:227-264.
4. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signaling. Nat. Rev. Immunol. 2005;5:375-386.
5. Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp. Hematol. 1999;27:1583-1592.
6. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004;202:8-32.
7. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science 2002;296:1653-1655.
8. Ihle JN. Cytokine receptor signaling. Nature 1995;377:591-594.
9. Matsuda T, Feng J, Witthuhn BA, Sekine Y, Ihle JN. Determination of the transphosphorylation sites of Jak2 kinase. Biochem. Biophys. Res. Commun. 2004;325:586-594.
10. Verma A, Platanias LC. Signaling via the interferon-alpha receptor in chronic myelogenous leukemia cells. Leak. Lymphoma 2002;43:703-709.
11. Li Y, Srivastava KK, Platanias LC. Mechanisms of type I interferon signaling in normal and malignant cells. Arch. Immunol. Ther. Exp. (Warsz.) 2004;52:156-163.
12. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-1635.
13. Domanski P, Nadeau OW, Platanias LC, Fish E, Kellum M, Pitha P, Colamonici OR. Differential use of the betaL subunit of the type 1 interferon (IFN) receptor determines signaling specificity for IFNalpha2 and IFNbeta. J. Biol. Chem. 1998;273:3144-3147.
14. Gongora R, Stephan RP, Schreiber RD, Cooper MD. Stat-1 is not essential for inhibition of B lymphopoiesis. J. Immunol. 2000;165:2362-2366.
15. Uddin S, Fish EN, Sher D, Gardziola C, Colamonici OR, Kellum M, Pitha PM, White MF, Platanias LC. The IRS pathway operates distinctively from the Stat pathway in hematopoietic cells and transduces common and distinct signals during engagement of the insulin or interferon-alpha receptors. Blood 1997;90:2574-2582.
16. Uddin S, Majchrzak B, Wang PC, Modi S, Khan MK, Fish EN, Platanias LC. Interferon-dependent activation of the serine kinase PI3′-kinase requires engagement of the IRS pathway but not the Stat pathway. Biochem. Biophys. Res. Commun. 2000;270:158-162.
17. Alsayed Y, Uddin S, Ahmad S, Majchrzak B, Druker BJ, Fish EN, Platanias LC. IFN-gamma activates the C3G/Rap1 signaling pathway. J. Immunol. 2000;164:1800-1806.
18. Verma A, Deb DK, Sassano A, Uddin S, Varga J, Wickrema A, Platanias LC. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J. Biol. Chem. 2002;277:7726-7735.
19. Verma A, Deb DK, Sassano A, Kambhampati S, Wickrema A, Uddin S, Mohindru M, Van Besien K, Platanias LC. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine- induced hemopoietic suppression in aplastic anemia. J. Immunol. 2002;168:5984-5988.
20. Uddin S, Majchrzak B, Woodson J, Arunkumar P, Alsayed Y, Pine R, Young PR, Fish EN, Platanias LC. Activation of the p38 mitogen-activated protein kinase by type 1 interferons. J. Biol. Chem. 1999;274:30127-30131.
21. David M, Petricoin E 3rd, Benjamin C, Pine R, Weber MJ, Larner AC. Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through Stat proteins. Science 1995;269:1721-1723.
22. Brachmann SM, Yballe CM, Innocenti M, Deane JA, Fruman DA, Thomas SM, Cantley LC. Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Mol. Cell. Biol. 2005;25:2593-2606.
23. Deane JA, Trifilo MJ, Yballe CM, Choi S, Lane TE, Fruman DA. Enhanced T cell proliferation in mice lacking the p85beta subunit of phosphoinositide 3-kinase. J. Immunol. 2004;172:6615-6625.
24. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol. Cell. Biol. 2002;22:965-977.
25. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657.
26. Deane JA, Fruman DA. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu. Rev. Immunol. 2004;22:563-598.
27. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu. Rev. Biochem. 1998;67:481-507.
28. Aksoy IA, Ramsey MJ, Fruman DA, Aksoy S, Cantley LC, Tucker JD, Roberts TM. Mouse phosphoinositide 3-kinase p110alpha gene: cloning, structural organization, and localization to chromosome 3 band B. Biochem. Biophys. Res. Commun. 1999;262:438-442.
29. Levy-Toledano R, Taouis M, Blaettler DH, Corden P, Taylor SI. Insulin- induced activation of phosphatidyl inositol 3-kinase. Demonstration that the p85 subunit binds directly to the COOH terminus of the insulin receptor in intact cells. J. Biol. Chem. 1994;269:31178-31182.
30. Wu H, Windmiller DA, Wang L, Backer JM. YXXM motifs in the PDGF- beta receptor serve dual roles as phosphoinositide 3-kinase binding motifs and tyrosine-based endocytic sorting signals. J. Biol. Chem. 2003;278:40425-40428.
31. Backer JM, Myers MG Jr, Shoelson SE, Chin DJ, Sun XJ, Miralpeix M, Hu P, Margolis B, Skolnik EY, Schlessinger J, et al. Phosphatidylinositol 3′- kinase is activated by association with IRS-1 during insulin stimulation. EMBO J. 1992;11:3469-3479.
32. White MF. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem. 1998;182:3-11.
33. Cai D, Dhe-Paganon S, Melendez PA, Lee J, Shoelson SE. Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5. J. Biol. Chem. 2003;278:25323-25330.
34. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, White MF. Structure of the insulin receptor substrate 1RS-1 defines a unique signal transduction protein. Nature 1991;352:73-77.
35. Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MG Jr, Glasheen E, Lane WS, Pierce JH, White MF. Role of IRS-2 in insulin and cytokine signaling. Nature 1995;377:173-177.
36. White MF, Maron R, Kahn CR. Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells. Nature 1985;318:183-186.
37. Smith-Hall J, Pons S, Patti ME, Burks DJ, Yenush L, Sun XJ, Kahn CR, White MF. The 60 kDa insulin receptor substrate functions like an 1RS protein (pp60IRS3) in adipose cells. Biochemistry 1997;36:8304-8310.
38. Bruning JC, Winnay J, Cheatham B, Kahn CR. Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. Mol Cell Biol. 1997;17:1513-1521.
39. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002;2:489-501.
40. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 1999;96:4240-4245.
41. Rohrschneider LR, Fuller JF, Wolf I, Liu Y, Lucas DM. Structure, function, and biology of SHIP proteins. Genes Dev. 2000;14:505-520.
42. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15:6541-6551.
43. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med. 2005;9:59-71.
44. Persad S, Attwell S, Gray V, Mawjin, Deng JT, Leung D, Yan J, Sanghera J, Walsh MP, Dedhar S. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J. Biol. Chem. 2001;276:27462- 27469.
45. Uddin S, Yenush L, Sun XJ, Sweet ME, White MF, Platanias LC. Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3′-kinase. J. Biol. Chem. 1995;270:15938-15941.
46. Platanias LC, Uddin S, Yetter A, Sun XJ, White MF. The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2. J. Biol. Chem. 1996;271:278-282.
47. Burfoot MS, Rogers NC, Watling D, Smith JM, Pons S, Paonessaw G, Pellegrini S, White MF, Kerr IM. Janus kinase-dependent activation of insulin receptor substrate 1 in response to interleukin-4, oncostatin M, and the interferons. J. Biol. Chem. 1997;272:24183-24190.
48. Cengel KA, Freund GG. JAK1-dependent phosphorylation of insulin receptor substrate-1 (IRS-1) is inhibited by IRS-1 serine phosphorylation. J. Biol. Chem. 1999;274:27969-27974.
49. Hartman ME, Villela-Bach M, Chen J, Freund GG. Frap-dependent serine phosphorylation of IRS-1 inhibits IRS-1 tyrosine phosphorylation. Biochem. Biophys. Res. Commun. 2001;280:776-781.
50. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-250.
51. Wen Z, Darnell JE Jr. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 1997;25:2062-2067.
52. Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene 2000;19:2628-2637.
53. Varinou L, Ramsauer K, Karaghiosoff M, Kolbe T, Pfeffer K, Muller M, Decker T. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. Immunity 2003;19:793-802.
54. + and CaMKII for Stat1 Ser-727 phosphorylation in response to IFN-gamma. Proc. Natl. Acad. Sci. USA 2002;99:5971-5976.
55. Nguyen H, Ramana CV, Bayes J, Stark GR. Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J. Biol. Chem. 2001;276:33361-33368.
56. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 1998;281:2042-2045.
57. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 2000;346:561-576.
58. Uddin S, Sassano A, Deb DK, Verma A, Majchrzak B, Rahman A, Malik AB, Fish EN, Platanias LC. Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J. Biol. Chem. 2002;277:14408-14416.
59. Deb DK, Sassano A, Lekmine F, Majchrzak B, Verma A, Kambhampati S, Uddin S, Rahman A, Fish EN, Platanias LC. Activation of protein kinase C delta by IFN- gamma. J. Immunol. 2003;171:267-273.
60. Kaur S, Parmar S, Smith J, Katsoulidis E, Li Y, Sassano A, Majchrzak B, Uddin S, Tallman MS, Fish EN, Platanias LC. Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells. Exp. Hematol. 2005;33:550-557.
61. Devries TA, Kalkofen RL, Matassa AA, Reyland ME. Protein kinase C delta regulates apoptosis via activation of STAT1. J. Biol. Chem. 2004;279:45603- 45612.
62. Choudhury GG. A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase C epsilon, and MAPK in mesangial cells regulates interferon-gamma-induced STAT1 alpha transcriptional activation. J. Biol. Chem. 2004;279:27399-27409.
63. Ferrari S, Thomas G. S6 phosphorylation and the p70s6k/p85s6k. Crit. Rev. Biochem. Mol. Biol. 1994;29:385-413.
64. Chou MM, Blenis J. The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signaling. Curr. Opin. Cell. Biol. 1995;7:806-814.
65. Hay N, Soneberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926-1945.
66. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004;4:335-348.
67. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 2001;15:2852-2864.
68. Potter CJ, Huang H, Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling regulating cell growth, cell proliferation, and organ size. Cell 2001;105:357-368.
69. Gao X, Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 2001;15:1383-1392.
70. Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, Ru B, Pan D. Tsc tumour suppressor proteins antagonize amino-acid-TOR signaling. Nat. Cell. Biol. 2002;4:699-704.
71. Green AJ, Ssmith M, Yates JR. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat. Genet. 1994;6:193-196.
72. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell. Biol. 2003;5:578-581.
73. Gromov PS, Madsen P, Tomerup N, Celis JE. A novel approach for expression cloning of small GTPases: identification, tissue distribution, and chromosome mapping of the human homolog of rheb. FEBS Lett. 1995;377:221-226.
74. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003;17:1829-1834.
75. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr. Biol. 2005;15:702-713.
76. Chiang GG, Abraham RT. Phosphorylation of mTOR at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem. 2005;280:25485-25490.
77. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 2002;10:151-162.
78. Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell. Biol. 2002;4:658-665.
79. Lekmine F, Uddin S, Sassano A, Parmar S, Brachmann SM, Majchrzak B, Sonenberg N, Hay N, Fish EN, Platanias LC. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type 1 interferons. J. Biol. Chem. 2003;278:27772-27780.
80. Lekmine F, Sassano A, Uddin S, Smith J, Majchrzak B, Brachmann SM, Hay N, Fish EN, Platanias LC. Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp. Cell Res. 2004;295:173-182.
81. Parmar S, Smith J, Sassano A, Uddin S, Katsoulidis E, Majchrzak B, Kambhampati S, Eklund EA, Tallman MS, Fish EN, Platanias LC. Differential regulation of the p70 S6 kinase pathway by interferon-α and imatinib mesylate (ST1571) in chronic myelogenous leukemia cells. Blood 2005;106:2436-2443.
82. Wang K, Scheel-Toellner D, Wong SH, Craddock R, Caamano J, Akbar AN, Salmon M, Lord JM. Inhibition of neutrophil apoptosis by type 1 IFN depends on cross-talk between phosphoinositol 3-kinase, protein kinase C-delta, and NF-kappa B signaling pathways. J. Immunol. 2003;171:1035-1041.
83. Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB, Pfeffer LM. Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J. Biol. Chem. 2001;276:13756-13761.
84. Ruuth K, Carlsson L, Hallberg B, Lundgren E. Interferon-alpha promotes survival of human primary B-lymphocytes via phosphatidylinositol 3- kinase. Biochem. Biophys. Res. Commun. 2001;284:583-586.
85. Barca O, Ferre S, Seoane M, Prieto JM, Lema M, Senaris R, Arce VM. Interferon beta promotes survival in primary astrocytes through phosphatidylinositol 3-kinase. J. Neuroimmunol. 2003;139:155-159.
86. Thyrell L, Hjortsberg L, Arulampalam V, Panaretakis T, Uhles S, Dagnell M, Zhivotovsky B, Leibiger I, Grander D, Pokrovskaja K. Interferon alpha- induced apoptosis in tumor cells is mediated through the phosphoinositide 3- kinase/mammalian target of rapamycin signaling pathway. J. Biol. Chem. 2004;279:24152-24162.